
検索結果 20 件
| JaLCDOI | 10.18926/AMO/68724 |
|---|---|
| フルテキストURL | 79_3_167.pdf |
| 著者 | Kanaji, Nobuhiro| Nishii, Kazuya| Tsubata, Yukari| Nakao, Mika| Okuno, Takae| Okawa, Sachi| Takata, Kenji| Kodani, Masahiro| Yamasaki, Masahiro| Fujitaka, Kazunori| Kubota, Tetsuya| Inoue, Masaaki| Watanabe, Naoki| Hotta, Katsuyuki| CS-Lung-003 Investigator| |
| 抄録 | This prospective observational study investigated the clinical status of patients with advanced non-small cell lung cancer (NSCLC) treated with cytotoxic chemotherapy+an immune checkpoint inhibitor (chemo + IO) as first-line treatment in a real-world setting. The cases of 98 patients treated with chemo + IO were prospectively collected and analyzed for effectiveness and safety. The response rate to chemo + IO was 46.9%, and the disease control rate was 76.5%. The median progression-free survival and overall survival (OS) in the total population were 5.2 and 22.3 months, respectively. The patients positive for PD-L1 (≥ 1%) showed significantly longer OS than the negative group (<1%) (median 26.7 vs. 18.7 months, p=0.04). Pre-existing interstitial lung disease (ILD) was associated with shorter OS than the absence of ILD (median 9.0 vs. 22.6 months, p<0.01). Immunerelated adverse events (irAEs) were observed in 28 patients (28.6%). The most frequent irAE was ILD (n=11); Grade 1 (n=1 patient), G2 (n=5), G3 (n=4), and only a single patient with a G5 irAE. In this CS-Lung-003 study, first-line chemo + IO in a real-world setting showed good effectiveness, comparable to that observed in international clinical trials. In real-world practice, chemo + IO is a promising and steadfast strategy. |
| キーワード | non-small cell lung cancer real-world first-line immune checkpoint inhibitor combined immunotherapy |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2025-06 |
| 巻 | 79巻 |
| 号 | 3号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 167 |
| 終了ページ | 176 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2025 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| フルテキストURL | fulltext.pdf |
|---|---|
| 著者 | Chen, Yuehua| Ohara, Toshiaki| Hamada, Yusuke| Wang, Yuze| Tian, Miao| Noma, Kazuhiro| Tazawa, Hiroshi| Fujisawa, Masayoshi| Yoshimura, Teizo| Matsukawa, Akihiro| |
| キーワード | Colorectal cancer Microsatellite stable Hypoxia-inducible factor Immune checkpoint inhibitors |
| 備考 | The version of record of this article, first published in Cancer Immunology, Immunotherapy, is available online at Publisher’s website: http://dx.doi.org/10.1007/s00262-025-04067-3| |
| 発行日 | 2025-05-09 |
| 出版物タイトル | Cancer Immunology, Immunotherapy |
| 巻 | 74巻 |
| 号 | 7号 |
| 出版者 | Springer |
| 開始ページ | 192 |
| ISSN | 0340-7004 |
| NCID | AA00598499 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © The Author(s) 2025 |
| 論文のバージョン | publisher |
| PubMed ID | 40343532 |
| DOI | 10.1007/s00262-025-04067-3 |
| Web of Science KeyUT | 001485530100001 |
| 関連URL | isVersionOf https://doi.org/10.1007/s00262-025-04067-3 |
| フルテキストURL | fulltext.pdf |
|---|---|
| 著者 | Kuribayashi, Tadahiro| Kinoshita, Rie| Ninomiya, Kiichiro| Makimoto, Go| Kubo, Toshio| Rai, Kammei| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki| Toyooka, Shinichi| Sakaguchi, Masakiyo| Ohashi, Kadoaki| |
| キーワード | S100A8/A9 Lung cancer Immune checkpoint inhibitors |
| 備考 | The version of record of this article, first published in Scientific Reports, is available online at Publisher’s website: http://dx.doi.org/10.1038/s41598-025-87232-z| |
| 発行日 | 2025-01-20 |
| 出版物タイトル | Scientific Reports |
| 巻 | 15巻 |
| 号 | 1号 |
| 出版者 | Nature Portfolio |
| 開始ページ | 2577 |
| ISSN | 2045-2322 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © The Author(s) 2025 |
| 論文のバージョン | publisher |
| PubMed ID | 39833332 |
| DOI | 10.1038/s41598-025-87232-z |
| Web of Science KeyUT | 001400880600002 |
| 関連URL | isVersionOf https://doi.org/10.1038/s41598-025-87232-z |
| フルテキストURL | fulltext.pdf |
|---|---|
| 著者 | Ohtani, Tomoko| Kuroda, Shinji| Kanaya, Nobuhiko| Kakiuchi, Yoshihiko| Kumon, Kento| Hashimoto, Masashi| Yagi, Chiaki| Sugimoto, Ryoma| Kikuchi, Satoru| Kagawa, Shunsuke| Tazawa, Hiroshi| Urata, Yasuo| Fujiwara, Toshiyoshi| |
| キーワード | Oncolytic adenovirus p53 Dendritic cells Anti-tumor immunity Exosome |
| 備考 | The version of record of this article, first published in Cancer Immunology, Immunotherapy, is available online at Publisher’s website: http://dx.doi.org/10.1007/s00262-024-03849-5| |
| 発行日 | 2024-11-05 |
| 出版物タイトル | Cancer Immunology, Immunotherapy |
| 巻 | 74巻 |
| 号 | 1号 |
| 出版者 | Springer Science and Business Media LLC |
| 開始ページ | 12 |
| ISSN | 1432-0851 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © The Author(s) 2024 |
| 論文のバージョン | publisher |
| PubMed ID | 39499326 |
| DOI | 10.1007/s00262-024-03849-5 |
| Web of Science KeyUT | 001350703400001 |
| 関連URL | isVersionOf https://doi.org/10.1007/s00262-024-03849-5 |
| フルテキストURL | fulltext.pdf |
|---|---|
| 著者 | Morinaga, Takao| Inozume, Takashi| Kawazu, Masahito| Ueda, Youki| Sax, Nicolas| Yamashita, Kazuo| Kawashima, Shusuke| Nagasaki, Joji| Ueno, Toshihide| Lin, Jason| Ohara, Yuuki| Kuwata, Takeshi| Yukami, Hiroki| Kawazoe, Akihito| Shitara, Kohei| Honobe-Tabuchi, Akiko| Ohnuma, Takehiro| Kawamura, Tatsuyoshi| Umeda, Yoshiyasu| Kawahara, Yu| Nakamura, Yasuhiro| Kiniwa, Yukiko| Morita, Ayako| Ichihara, Eiki| Kiura, Katsuyuki| Enokida, Tomohiro| Tahara, Makoto| Hasegawa, Yoshinori| Mano, Hiroyuki| Suzuki, Yutaka| Nishikawa, Hiroyoshi| Togashi, Yosuke| |
| 発行日 | 2022-07-28 |
| 出版物タイトル | Cancer Research Communications |
| 巻 | 2巻 |
| 号 | 7号 |
| 出版者 | American Association for Cancer Research |
| 開始ページ | 739 |
| 終了ページ | 753 |
| ISSN | 2767-9764 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © 2022 The Authors |
| 論文のバージョン | publisher |
| PubMed ID | 36923281 |
| DOI | 10.1158/2767-9764.CRC-22-0050 |
| Web of Science KeyUT | 001048412300001 |
| 関連URL | isVersionOf https://doi.org/10.1158/2767-9764.CRC-22-0050 |
| フルテキストURL | fulltext20221215-1.pdf figures20221215-1.pdf Supple_Figures20221215-1.pdf Supple_Table20221215-1.pdf |
|---|---|
| 著者 | Kajiwara, Yoshinori| Tazawa, Hiroshi| Yamada, Motohiko| Kanaya, Nobuhiko| Fushimi, Takuro| Kikuchi, Satoru| Kuroda, Shinji| Ohara, Toshiaki| Noma, Kazuhiro| Yoshida, Ryuichi| Umeda, Yuzo| Urata, Yasuo| Kagawa, Shunsuke| Fujiwara, Toshiyoshi| |
| キーワード | Pancreatic cancer Chemoresistance MDSC GM-CSF Oncolytic virus |
| 備考 | This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s00262-022-03334-x| This full-text of the article will be available in Nov. 2023.| |
| 発行日 | 2022-11-27 |
| 出版物タイトル | Cancer Immunology, Immunotherapy |
| 巻 | 72巻 |
| 号 | 5号 |
| 出版者 | Springer Science and Business Media LLC |
| 開始ページ | 1285 |
| 終了ページ | 1300 |
| ISSN | 0340-7004 |
| NCID | AA00598499 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 |
| 論文のバージョン | author |
| PubMed ID | 36436021 |
| DOI | 10.1007/s00262-022-03334-x |
| Web of Science KeyUT | 000889040300003 |
| 関連URL | isVersionOf https://doi.org/10.1007/s00262-022-03334-x |
| JaLCDOI | 10.18926/AMO/64024 |
|---|---|
| フルテキストURL | 76_5_489.pdf |
| 著者 | Matsumoto, Yuji| Ichikawa, Tomotsugu| Kurozumi, Kazuhiko| Date, Isao| |
| 抄録 | Glioblastoma (GBM) is a fatal primary malignant brain tumor in adults. Despite decades of research, the prognosis for GBM patients is still disappointing. One major reason for the intense therapeutic resistance of GBM is inter- and intra-tumor heterogeneity. GBM-intrinsic transcriptional profiling has suggested the presence of at least three subtypes of GBM: the proneural, classic, and mesenchymal subtypes. The mesenchymal subtype is the most aggressive, and patients with the mesenchymal subtype of primary and recurrent tumors tend to have a worse prognosis compared with patients with the other subtypes. Furthermore, GBM can shift from other subtypes to the mesenchymal subtype over the course of disease progression or recurrence. This phenotypic transition is driven by diverse tumor-intrinsic molecular mechanisms or microenvironmental factors. Thus, better understanding of the plastic nature of mesenchymal transition in GBM is pivotal to developing new therapeutic strategies. In this review, we provide a comprehensive overview of the current understanding of the elements involved in the mesenchymal transition of GBM and discuss future perspectives. |
| キーワード | glioma glioblastoma mesenchymal subtype mesenchymal transition heterogeneity |
| Amo Type | Review |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2022-10 |
| 巻 | 76巻 |
| 号 | 5号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 489 |
| 終了ページ | 502 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2022 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 36352795 |
| Web of Science KeyUT | 000884907100001 |
| JaLCDOI | 10.18926/AMO/63906 |
|---|---|
| フルテキストURL | 76_4_465.pdf |
| 著者 | Bekku, Kensuke| Tsugawa, Takuji| Tsuboi, Kazuma| Noda, Gaku| Inoue, Yousuke| Murao, Wataru| Ebara, Shin| |
| 抄録 | We aimed to identify the role of first-line monotherapy with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) in patients with metastatic RCC. Eligible patients were categorized into three groups (favorable, intermediate, and poor risk) according to the International Metastatic RCC Database Consortium risk criteria. Overall survival (OS) was the primary endpoint. Survival was compared using the log-rank test. A total of 108 patients were retrospectively analyzed. The numbers of patients in the favorable-, intermediate-, and poor-risk groups were 32 (30%), 66 (61%), and 10 (9%), repestively. The median OS values in the entire cohort was 36 months (95% confidence interval [CI] 29-53). The median OS in the favorable, intermediate, and poor risk groups were 94 months (95% CI: 43-Not reached), 30 months (95% CI: 20-38), and 8 months (95% CI: 0-Not reached), respectively (p<0.05). Prior nephrectomy, clear cell histology, clinical T stage ≤2, no metastasis at the time of diagnosis, nivolumab beyond first-line therapy, and objective response to VEGFR-TKIs were factors significantly prolonging OS on univariate analysis. VEGFR-TKI monotherapy as first-line therapy was an effective treatment option for patients with metastatic clear cell RCC with favorable risk. |
| キーワード | metastatic renal cell carcinoma molecular-targeted therapy immuno-checkpoint inhibitor real-world setting |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2022-08 |
| 巻 | 76巻 |
| 号 | 4号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 465 |
| 終了ページ | 472 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2022 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 36123162 |
| フルテキストURL | fulltext.pdf |
|---|---|
| 著者 | Miyamoto, Ai| Honjo, Tomoko| Masui, Mirei| Kinoshita, Rie| Kumon, Hiromi| Kakimi, Kazuhiro| Futami, Junichiro| |
| キーワード | autoantibody biomarker protein engineering cancer-immunity cycle immune monitoring cancer testis antigens |
| 発行日 | 2022-05-04 |
| 出版物タイトル | Frontiers In Oncology |
| 巻 | 12巻 |
| 出版者 | FRONTIERS MEDIA SA |
| 開始ページ | 869393 |
| ISSN | 2234-943X |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © 2022 Miyamoto, Honjo, Masui, Kinoshita, Kumon, Kakimi and Futami. |
| 論文のバージョン | publisher |
| PubMed ID | 35600379 |
| DOI | 10.3389/fonc.2022.869393 |
| Web of Science KeyUT | 000797484100001 |
| 関連URL | isVersionOf https://doi.org/10.3389/fonc.2022.869393 |
| フルテキストURL | fulltext20211206-3.pdf |
|---|---|
| 著者 | Kawashima, Shusuke| Inozume, Takashi| Kawazu, Masahito| Ueno, Toshihide| Nagasaki, Joji| Tanji, Etsuko| Honobe, Akiko| Ohnuma, Takehiro| Kawamura, Tatsuyoshi| Umeda, Yoshiyasu| Nakamura, Yasuhiro| Kawasaki, Tomonori| Kiniwa, Yukiko| Yamasaki, Osamu| Fukushima, Satoshi| Ikehara, Yuzuru| Mano, Hiroyuki| Suzuki, Yutaka| Nishikawa, Hiroyoshi| Matsue, Hiroyuki| Togashi, Yosuke| |
| 発行日 | 2021-11 |
| 出版物タイトル | Journal for ImmunoTherapy of Cancer |
| 巻 | 9巻 |
| 号 | 11号 |
| 出版者 | BMJ |
| 開始ページ | e003134 |
| ISSN | 2051-1426 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © Author(s) (or their employer(s)) 2021. |
| 論文のバージョン | publisher |
| DOI | 10.1136/jitc-2021-003134 |
| Web of Science KeyUT | 000720981900005 |
| 関連URL | isVersionOf https://doi.org/10.1136/jitc-2021-003134 |
| フルテキストURL | fulltext.pdf |
|---|---|
| 著者 | Lin, Wenfeng| Li, Chaoming| Xu, Naijin| Watanabe, Masami| Xue, Ruizhi| Xu, Abai| Araki, Motoo| Sun, Ruifen| Liu, Chunxiao| Nasu, Yasutomo| Huang, Peng| |
| キーワード | prostate cancer PLGA indocyanine green resiquimod photothermal therapy immunotherapy |
| 発行日 | 2021-04-12 |
| 出版物タイトル | International Journal of Nanomedicine |
| 巻 | 16巻 |
| 出版者 | Dove Medical Press Ltd. |
| 開始ページ | 2775 |
| 終了ページ | 2787 |
| ISSN | 1178-2013 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © 2021 Lin et al. |
| 論文のバージョン | publisher |
| PubMed ID | 33880023 |
| DOI | 10.2147/IJN.S301552 |
| NAID | 120007034434 |
| Web of Science KeyUT | 000639251200001 |
| 関連URL | isVersionOf https://doi.org/10.2147/IJN.S301552 |
| JaLCDOI | 10.18926/AMO/60802 |
|---|---|
| フルテキストURL | 74_5_423.pdf |
| 著者 | Hirabae, Atsuko| Ichihara, Eiki| Sunami, Ryota| Ota, Moeko| Iwamoto, Yoshitaka| Maeda, Yoshinobu| Kiura, Katsuyuki| |
| 抄録 | We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks. |
| キーワード | lung cancer immune checkpoint inhibitors pembrolizumab hyperprogression |
| Amo Type | Case Report |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2020-10 |
| 巻 | 74巻 |
| 号 | 5号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 423 |
| 終了ページ | 425 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2020 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 33106698 |
| Web of Science KeyUT | 000581970100007 |
| NAID | 120006892928 |
| フルテキストURL | fulltext.pdf Graphical_Abstract.pptx Figure1-6.pdf Supp_Info.pdf |
|---|---|
| 著者 | Kanaya, Nobuhiko| Kuroda, Shinji| Kakiuchi, Yoshihiko| Kumon, Kento| Tsumura, Tomoko| Hashimoto, Masashi| Morihiro, Toshiaki| Kubota, Tetsushi| Aoyama, Katsuyuki| Kikuchi, Satoru| Nishizaki, Masahiko| Kagawa, Shunsuke| Tazawa, Hiroshi| Mizuguchi, Hiroyuki| Urata, Yasuo| Fujiwara, Toshiyoshi| |
| キーワード | immune checkpoint programmed death-1 oncolytic adenovirus combined immunotherapy immunogenic cell death tumor infiltrating lymphocytes CD8 abscopal effect |
| 発行日 | 2020-01-10 |
| 出版物タイトル | Molecular Therapy |
| 巻 | 28巻 |
| 号 | 3号 |
| 出版者 | Cell Press |
| 開始ページ | 794 |
| 終了ページ | 804 |
| ISSN | 15250016 |
| NCID | AA11475060 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 論文のバージョン | author |
| PubMed ID | 31991110 |
| DOI | 10.1016/j.ymthe.2020.01.003 |
| Web of Science KeyUT | 000518887200012 |
| 関連URL | isVersionOf https://doi.org/10.1016/j.ymthe.2020.01.003 |
| フルテキストURL | PlosOne_2018_e0191109.pdf |
|---|---|
| 著者 | Eguchi, Takanori| Sogawa, Chiharu| Okusha, Yuka| Uchibe, Kenta| Iinuma, Ryosuke| Ono, Kisho| Nakano, Keisuke| Murakami, Jun| Itoh, Manabu| Arai, Kazuya| Fujiwara, Toshifumi| Namba, Yuri| Murata, Yoshiki| Ohyama, Kazumi| Shimomura, Manami| Okamura, Hirohiko| Takigawa, Masaharu| Nakatsura, Tetsuya| Kozaki, Kenichi| Okamoto, Kuniaki| Calderwood, Stuart K.| |
| 発行日 | 2018-02-07 |
| 出版物タイトル | PlosOne |
| 巻 | 13巻 |
| 号 | 2号 |
| 出版者 | Public Library Science |
| 開始ページ | e0191109 |
| ISSN | 19326203 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja |
| 論文のバージョン | publisher |
| PubMed ID | 29415026 |
| DOI | 10.1371/journal.pone.0191109 |
| Web of Science KeyUT | 000424325300015 |
| 関連URL | isVersionOf https://doi.org/10.1371/journal.pone.0191109 |
| タイトル(別表記) | An investigator initiated phase II clinical trial of tamibarotene (AM80G) for chronic graft-versus-host disease |
|---|---|
| フルテキストURL | 127_133.pdf |
| 著者 | 西森 久和| 前田 嘉信| |
| キーワード | 臨床研究中核病院 慢性GVHD タミバロテン 同種造血幹細胞移植 Th17 |
| 出版物タイトル | 岡山医学会雑誌 |
| 発行日 | 2015-08-03 |
| 巻 | 127巻 |
| 号 | 2号 |
| 開始ページ | 133 |
| 終了ページ | 137 |
| ISSN | 0030-1558 |
| 関連URL | isVersionOf https://doi.org/10.4044/joma.127.133 |
| 言語 | 日本語 |
| 著作権者 | Copyright (c) 2015 岡山医学会 |
| 論文のバージョン | publisher |
| DOI | 10.4044/joma.127.133 |
| NAID | 130005096255 |
| 著者 | Nobuoka, Daisuke| Yoshikawa, Toshiaki| Takahashi, Mari| Iwama, Tatsuaki| Horie, Kazutaka| Shimomura, Manami| Suzuki, Shiro| Sakemura, Noriko| Nakatsugawa, Munehide| Sadamori, Hiroshi| Yagi, Takahito| Fujiwara, Toshiyoshi| Nakatsura, Tetsuya| |
|---|---|
| 発行日 | 2013-04 |
| 出版物タイトル | Cancer Immunology, Immunotherapy |
| 巻 | 62巻 |
| 号 | 4号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 森下 亮二| |
|---|---|
| 発行日 | 1994 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 106巻 |
| 号 | 3-4号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 洲脇 俊充| |
|---|---|
| 発行日 | 1994-08 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 106巻 |
| 号 | 7-8号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 中川 和彦| 野口 雄司| 奥村 英雄| 佐藤 修一郎| 田中 志幸| 下野 玄英| アリ・エルディブ アリ モハメド| 青江 基| 小野 俊朗| 上中 明子| 大原 信哉| 吉野 正| 山下 和城| 角田 司| 清水 信義| 中山 睿一| |
|---|---|
| 発行日 | 2007-09-03 |
| 出版物タイトル | 岡山医学会雑誌 |
| 巻 | 119巻 |
| 号 | 2号 |
| 資料タイプ | 学術雑誌論文 |
| 著者 | 増田 浩三| |
|---|---|
| 発行日 | 2007-03-23 |
| 出版物タイトル | |
| 資料タイプ | 学位論文 |